Pharmacotherapy of Raynaud's phenomenon

Drugs

Volumn 52, Issue 5, 1996, Pages 682-695

  Belch, Jill J F ^a   Ho, Meilien ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DILTIAZEM; ESSENTIAL FATTY ACID; INOSITOL NICOTINATE; NAFTIDROFURYL; NIFEDIPINE; PENTOXIFYLLINE; PROSTAGLANDIN DERIVATIVE; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ANKLE EDEMA; ATHEROSCLEROSIS; CONNECTIVE TISSUE DISEASE; DIET SUPPLEMENTATION; DISEASE SEVERITY; DRUG EFFICACY; ERYTHROCYTE; GLOVE; HEADACHE; HOT FLUSH; HUMAN; LEUKOCYTE; LUMBAR SYMPATHECTOMY; MICROCIRCULATION; OCCUPATIONAL DISEASE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RAYNAUD PHENOMENON; REVIEW; RISK FACTOR; SHOE; SYMPTOM; THROMBOCYTE ACTIVATION; VASCULAR ENDOTHELIUM; VASOSPASM; VIBRATION;

EID: 0029823375     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199652050-00006     Document Type: Review

References (73)

1. Porter JM, Bardona EJ, Baur GM, et al. The clinical significance of Raynaud's syndrome. Surgery 1976; 80: 756-64
2. Maricq HR, Weinrich MC, Keil JE, et al. Prevalence of Raynaud's phenomenon in the general population. J Chronic Dis 1986; 39: 423-7
3. Olsen N, Neilsen SL. Prevalence of primary Raynaud's phenomena in young females. Scand J Clin Lab Invest 1978; 37: 761-4
4. Edwards JM, Porter JM. Associated disease in patients with Raynaud's syndrome. Vasc Med Rev 1990; 1: 51-8
5. Goodfield MJD, Hume A, Rowell, NR. The acute effects of cigarette smoking on cutaneous blood flow in smoking and non-smoking subjects with and without Raynaud's phenomenon. Br J Rheumatol 1990; 29: 89-91
6. de Trafford JC, Lafferty K, Potter CE, et al. An epidemiological survey of Raynaud's phenomenon. Eur J Vasc Surg 1988; 2 (3): 167-70
7. Belch JJF, Land D, Park RHR, et al. Decreased oesophageal blood flow in patients with Raynaud's phenomenon. Br J Rheumatol 1988; 27: 426-30
8. Porter JM, Rivers SP, Anderson CJ, et al. Evaluation and management of patients with Raynaud's syndrome. Am J Surg 1987; 142: 183-9
9. Allen EV, Brown GE. Raynaud's disease: a critical review of minimal requisites for diagnosis. Am J Med Sci 1932; 183: 187-200
10. Kallenberg CGM, Wouda AA, Hoet MA, et al. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis 1988; 47: 634-41
11. Kallenberg CG, Wouda AA, Hoel MH. Systemic involvement and immunological findings in patients presenting with Raynaud's phenomenon. Am J Med 1980; 69: 675-80
12. Maricq HR, Johnson MN, Whetstone CC. Capillary abnormalities in polyvinyl chloride production workers in examinations by in vivo microscopy. JAMA 1976; 236: 1368-71
13. Taylor W. The hand-arm vibration syndrome: secondary Raynaud's phenomenon of occupational origin. Proc R Coll Phys Edinb 1989; 19: 7-14
14. Lewis T. Raynaud's disease and preganglionic sympathectomy. Clin Sci 1938; 3: 320-36
15. Freedman RR, Sabharal SC, Desai N. Increased alpha-adrenergic responsiveness in idiopathic Raynaud's disease. Arth Rheum 1989; 32 (1): 61-5
16. Brotzu G, Falchi S, Mannu B, et al. The importance of presynaptic beta receptors in Raynaud's disease. J Vasc Surg 1989; 9 (6): 767-71
17. Carter SA, Dean E, Kroeger EA. Apparent finger systolic pressures during cooling in patients with Raynaud's syndrome. Circulation 1988; 77 (5): 988-96
18. Lau C, O'Dowd A, Belch JJF. White cell activation in the Raynaud's phenomenon of systemic sclerosis and vibration induced white finger syndrome. Ann Rheum Dis 1992; 1 (2): 249-52
19. Belch JJF, Drury J, McLaughlin K, et al. Abnormal biochemical and cellular parameters in the blood of patients with Raynaud's phenomenon. Scott Med J 1987; 32 (1): 12-4
20. Belch JJF, Zoma AA, Richards IM, et al. Vascular damage and factor VIII related antigen in the rheumatic diseases. Rheumatol Int 1987; 7: 107-11
21. Belch JF, McLaren M, Anderson J, et al. Increased prostacyclin metabolites and decreased red cell deformability in patients with systemic sclerosis and Raynaud's syndrome. Prostaglandins Leukot Med 1985 Jan; 17: 1-9
22. Belch JJF, O'Dowd A, Forbes CF, et al. Platelet sensitivity to a prostacyclin analogue in systemic sclerosis. Br J Rheumatol 1986; 24: 346-50
23. Zamora MR, O'Brien RF, Rutherford RB, et al. Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon. Lancet 1990; 336: 1144-7
24. Kahaleh MB, Smith EA, Soma Y, et al. Effect of lymphotoxin and tissue necrosis factor on endothelial and connective cell growth and function. Clin Immunol Immunopathol 1988; 49: 261-72
25. LeRoy EC, Smith EA, Kahaleh MB, et al. A strategy for determining the pathogenesis of systemic sclerosis: is transforming growth factor-beta the answer? Arthritis Rheum 1989; 32: 817-25
26. Malamet R, Wise RA, Ettinger WH. Nifedipine in the treatment of Raynaud's phenomenon - evidence for inhibition of platelet activation. Am J Med 1985; 78 (4): 602-8
27. Smith CD, McKendry JR. Controlled trial of nifedipine in the treatment of Raynaud's phenomenon. Lancet 1982 Dec 11; 11: 1299-301
28. Roddeheffer RJ, Rommer JA, Wigley F, et al. Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon. N Engl J Med 1983; 308: 880-3
29. Sauza J, Kraus A, Gonzalez-Amaro R, et al. Effect of the calcium channel blocker nifedipine on Raynaud's phenomenon: a controlled double blind trial. J Rheumat 1984; 11 (3): 362-3
30. Kahan A, Weber S, Amor B, et al. Calcium entry blocking agents in digital vasospasm (Raynaud's phenomenon). Eur Heart J 1983; 4 Suppl. C: 123-9
31. Finch MB, Copeland S, Passmore AP, et al. A double-blind cross-over study of nifedipine retard in patients with Raynaud's phenomenon. Clin Rheumatol 1988, 7 (3): 359-65
32. Waller DG, Challenor VF, Francis DA, et al. Clinical and rheological effects of nifedipine in Raynaud's phenomenon. Br J Clin Pharmacol 1986; 22: 449-54
33. Kahan A, Amor B, Menkes CJ. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon. Ann Rheum Dis 1985; 44(1): 30-3
34. Leppert J, Jonasson T, Nilsson H. The effect of isradipine, a new calcium-channel antagonist, in patients with primary Raynaud's phenomenon: a single-blind dose-response study. Cardiovasc Drugs Ther 1989; 3 (3): 397-401
35. Cook NJ, Armstrong RD, Roper SMB, et al. Amlodipine in the treatment of Raynaud's phenomenon. Br J Rheumatol 1993; 32 (6): 524-5
36. Kinney EL, Nicholas GG, Gallo J, et al. The treatment of severe Raynaud's phenomenon with verapamil. J Clin Pharmacol 1982; 22: 74-6
37. Miller FW, Love LA. Prevention of predictable Raynaud's phenomenon by sublingual nifedipine. N Engl J Med 1987; 317: 1476
38. Smith CR, Rodeheffer RJ. Treatment of Raynaud's phenomenon with calcium channel blockers. Am J Med 1985; 78 Suppl. 2B: 39-42
39. Davinroy M, Mosnier M. Double-blind clinical evaluation of naftidrofuryl in Raynaud's phenomenon. Sem Hop 1993; 69 (36): 12-8
40. Nilsen KH. Effects of naftidrofuryl on microcirculatory cold sensitivity in Raynaud's phenomenon. BMJ 1979; 1: 20-1
41. Murphy R. The effect of inositol nicotinate (Hexopal) in patients with Raynaud's phenomenon. Clin Trials J 1985; 22 (6): 521-9
42. Sunderland GT, Belch JJF, Sturrock RD, et al. A double blind randomised placebo controlled trial of Hexopal in primary Raynaud's disease. Clin Rheumatol 1988; 7(1): 46-9
43. Aylward M. Hexopal in Raynaud's Disease. J Int Med Res 1979; 7: 484
44. Holti G. An experimentally controlled evaluation of the effect of inositol nicotinate upon the digital blood flow in patients with Raynaud's phenomenon. J Int Med Res 1979; 7: 473
45. Ring EFJ, Porto LO, Bacon PA. Quantitative thermal imaging to assess inositol nicotinate treatment for Raynaud's syndrome. J Int Med Res 1981; 9: 393-400
46. Stellin GP, Waxman K. Current and potential therapeutic effects of pentoxifylline. Compr Ther 1989; 15: 11-3
47. Mihajlovic D, Hadzi-Pesic LJ, Markovic V, et al. Experiences with pentoxifylline in the treatment of peripheral vascular disease. Curr Med Res Opin 1979; 6 Suppl. 4: 43-8
48. Schmidt C, Marquis P, Royer RJ, et al. Clinical and hemodynamic study of pentoxifylline in diseases of the peripheral vessels. Ann Med Nancy 1976; 15: 61-5
49. Neirotti M, Longo F, Molaschi M, et al. Functional vascular disease: treatment with pentoxifylline [abstract]. 28th Annual Meeting of the International College of Angiology. Nice. Angiology 1986; 37: 397-8
50. Stefenelli T, Silberbauer K, Glogar D. Pentoxifylline/placebo/ nifedipine in patients with Raynaud's phenomenon: influence on frequency of attacks and rewarming time. Klin Wochenschr 1986; 64: 1155-6
51. Newnam ED, Davis DE, Harrington TM. Double blind placebo controlled trial of pentoxifylline in the treatment of primary and secondary Raynaud's phenomenon [abstract no. D180]. Arthritis Rheum 1989; 34 (9): 193
52. Aylward M, Bater PA, Davies DE, et al. Long-term monitoring of the effects of thymoxamine hydrochloride tablets in the management of patients with Raynaud's disease. Curr Med Res Opin 1982; 8(3): 158-70
53. Jaffe GV, Grimshaw JJ. Thymoxamine for Raynaud's disease and chilblains. Br J Clin Pract 1980; 34: 11-2
54. Grigg MJ, Nicolaides AN, Papadakis K, et al. The efficacy of thymoxamine in primary Raynaud's phenomenon. Eur J Vasc Surg 1989; 3: 309-13
55. Belch JJF, Greer IA, McLaren M, et al. The effects of intravenous infusion of ZK36374, a synthetic prostacyclin derivative, on normal volunteers. Prostaglandins 1984; 28(1): 67-78
56. Belch JJF. Prostaglandins in Raynaud's phenomenon. In: Vane J, O'Grady J, editors. Therapeutic applications of prostaglandins. London: Edward Arnold, 1993: 219-39
57. 1 infusions for vascular insufficiency in progressive systemic sclerosis. Ann Rheum Dis 1981; 40: 350-4
58. Belch JJF, Drury JK, Capell H, et al. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome - a double-blind controlled trial. Lancet 1983; 1: 313-5
59. Rademaker M, Thomas RHM, Provost G, et al. Prolonged increase in digital blood flow following iloprost infusion in patients with systemic sclerosis. Postgrad Med J 1987; 63: 617-20
60. Wigley FM, Wise RA, Seibold JR, et al. Intravenous iloprost infusion in patients with Raynaud Phenomenon secondary to systemic sclerosis. Ann Intern Med 1994; 120: 199-206
61. Torley HI, Madhok R, Capell HA, et al. A double-blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases. Ann Rheum Dis 1991; 50: 800-4
62. Rademaker M, Cooke ED, Almond NE, et al. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double-blind randomised study. BMJ 1989; 298: 561-4
63. Lau CS, McLaren M, Saniabadi A, et al. The pharmacological effects of cicaprost, an oral prostacyclin analogue, in patients with Raynaud's syndrome secondary to systemic sclerosis - a preliminary study. Clin Exp Rheumatol 1991; 9: 271-3
64. Murai C, Sasaki T, Osaki H, et al. Oral limaprost for Raynaud's phenomenon. Lancet 1989; 1: 1218
65. Belch JJF, Capell HA, Cooke ED, et al. Oral iloprost as a treatment for Raynaud's syndrome: a double-blind multi-centre placebo controlled study. Ann Rheum Dis 1995; 54 (3): 197-200
66. 2 analogue, in treatment of Raynaud's phenomenon. Lancet 1985; 1: 1180-3
67. Belch JJF, Cormie J, Newman P, et al. Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome: a double-blind trial. Br J Clin Pharmacol 1983; 15: 1135-6
68. Belch JJF, Shaw B, O'Dowd A, et al. Evening primrose oil (Efamol) in the treatment of Raynaud's phenomenon: a double blind study. Thromb Haemost 1985; 54 (2): 490-4
69. DiGacomo RA, Kremer JM, Shah DM. Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study. Am J Med 1989; 86: 158-64
70. Coffmann JD, Clement DL, Creager MA, et al. International study of ketanserin in Raynaud's phenomenon. Am J Med 1989; 87: 264-8
71. Shawket S, Dickerson C, Hazleman B, et al. Prolonged effect of CGRP in Raynaud's patients: a double-blind randomised with prostacyclin. Br J Clin Pharmacol 1991; 32: 209-13
72. Bunker CB, Terenghi G, Springall DR, et al. Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon. Lancet 1990; 336: 1530-3
73. Hansteen V. Medical treatment in Raynaud's disease. Acta Chir Scand 1976; 465: 87-91